Stenting In Heart Attack Patients Cleared By FDA; Guidant’s Multi-Link Is First
This article was originally published in The Gray Sheet
Executive Summary
Guidant is now the only company with a coronary stent indicated for use in heart attack patients in the U.S. The firm announced Aug. 14 that the Multi-Link stent platform received FDA approval via PMA supplement
You may also be interested in...
Small-Vessel Pixel Stent Receives Alloy Upgrade In Next Generation – Guidant
Guidant expects FDA approval of its next-generation Pixel stent for small vessels within the coming weeks
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.